Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial

Duk Woo Park; Young Hak Kim; Hae Geun Song; Jung Min Ahn; Won Jang Kim; Jong Young Lee; Soo Jin Kang; Seung Whan Lee; Cheol Whan Lee; Seong Wook Park; Sung Cheol Yun; Ki Bae Seung; Tae Hyun Yang; Sang Gon Lee; Jae Hwan Lee; In Whan Seong; Sang Sig Cheong; Bong Ki Lee; Nae Hee Lee; Se Whan Lee; Seung Wook Lee; Keun Lee; Hyun Sook Kim; Doo Soo Jeon; Min Kyu Kim; Deuk Young Nah; Seung Jea Tahk; Seung Jung Park

doi:10.1016/j.jcin.2011.05.024

Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial

Duk Woo Park
, Young Hak Kim
, Hae Geun Song
, Jung Min Ahn
, Won Jang Kim
, Jong Young Lee
, Soo Jin Kang
, Seung Whan Lee
, Cheol Whan Lee
, Seong Wook Park
, Sung Cheol Yun
, Ki Bae Seung
, Tae Hyun Yang
, Sang Gon Lee
, Jae Hwan Lee
, In Whan Seong
, Sang Sig Cheong
, Bong Ki Lee
, Nae Hee Lee
, Se Whan Lee

Seung Wook Lee, Keun Lee, Hyun Sook Kim, Doo Soo Jeon, Min Kyu Kim, Deuk Young Nah, Seung Jea Tahk, Seung Jung Park

Department of Internal Medicine

University of Ulsan
Catholic Univ. of Korea Coll. Med.
Inje University
Chungnam National University
Kangwon National University
Soonchunhyang University
Kwangju Christian Hospital
Seoul Veterans Hospital
Hallym University
Dongguk University
Ajou University

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Abstract

Objectives: This study compared everolimus-eluting stents (EES) and sirolimus-eluting stents (SES) for long coronary lesions. Background: Outcomes remain relatively unfavorable for stent-based coronary intervention of lesions with long diseased segments. Methods: This randomized, multicenter, prospective trial compared the use of long EES with SES in 450 patients with long (<25 mm) native coronary lesions. The primary endpoint of the trial was in-segment late luminal loss at 9-month angiographic follow-up. Results: The EES and SES groups had similar baseline characteristics. Lesion length was 34.0 ± 15.4 mm in the EES group and 34.3 ± 13.5 mm in the SES group (p = 0.85). Nine-month angiographic follow-up was performed in 80% of the EES group and 81% of the SES group (p = 0.69). In-segment late loss as the primary study endpoint was significantly larger in the EES group than in the SES group (0.17 ± 0.41 mm vs. 0.09 ± 0.30 mm, p for noninferiority = 0.96, p for superiority = 0.04). The in-segment binary restenosis rate was also higher in the EES group than in the SES group (7.3% vs. 2.7%, p = 0.046). However, in-stent late loss (0.22 ± 0.43 mm vs. 0.18 ± 0.28 mm, p = 0.29) and in-stent binary restenosis rate (3.9% vs. 2.7%, p = 0.53) were similar among the 2 groups. The incidence of any clinical outcomes (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes) was not statistically different between the 2 groups. Conclusions: For patients with long native coronary artery disease, EES implantation was associated with greater angiographic in-segment late loss and higher rates of in-segment restenosis compared with SES implantation. However, clinical outcomes were both excellent and not statistically different. (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III [LONG-DES-III]; NCT01078038)

Original language	English
Pages (from-to)	1096-1103
Number of pages	8
Journal	JACC: Cardiovascular Interventions
Volume	4
Issue number	10
DOIs	https://doi.org/10.1016/j.jcin.2011.05.024
State	Published - Oct 2011

Bibliographical note

Funding Information:
This study was supported by funds from the CardioVascular Research Foundation, Seoul, Korea; a grant from the Korea Health 21 R & D Project, Ministry of Health & Welfare , Korea ( 0412-CR02-0704-0001 ); and Boston Scientific , Natick , Massachusetts . Dr. D.-W. Park has received research funding from Boston Scientific. Dr. Y.-H. Kim has received lecture fees from Cordis and Medtronic; and research funding from Boston Scientific. Dr. S.-J. Kang has received lecture fees from Boston Scientific. Dr. S.-W. Lee reports receiving lecture fees from Cordis and Boston Scientific. Dr. C. W. Lee has received lectures fees from Medtronic; and a research grant from Boston Scientific . Dr. S.-W. Park has received research grant support from Medtronic ; and research funding from Boston Scientific. Dr. K.-B. Seung has received lecture fees from Cordis and Boston Scientific. Dr. J.-H. Lee has received research funding from Boston Scientific. Dr. I.-W. Seong has received research grant support from Boston Scientific . Dr. S.-S. Cheong has received lecture fees from Cordis and Boston Scientific. Dr. N.-H. Lee has received lecture fees from Cordis and Boston Scientific. Dr. H.-S. Kim has received consulting fees from Abbott Vascular. Dr. D.-S. Jeon has received lecture fees from Cordis, Medtronic, and Boston Scientific. Dr. D.-Y. Nah has received lecture fees from Cordis and Medtronic. Dr. S.-J. Tahk has received lecture fees from Boston Scientific. Dr. S.-J. Park has received consulting fees from Cordis; lecture fees from Cordis, Medtronic, Boston Scientific, and Abbott; and research grant support from Cordis and Medtronic . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Keywords

angioplasty
coronary disease
stents

Access to Document

10.1016/j.jcin.2011.05.024

Fingerprint

Dive into the research topics of 'Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial'. Together they form a unique fingerprint.

Cite this

Park, D. W., Kim, Y. H., Song, H. G., Ahn, J. M., Kim, W. J., Lee, J. Y., Kang, S. J., Lee, S. W., Lee, C. W., Park, S. W., Yun, S. C., Seung, K. B., Yang, T. H., Lee, S. G., Lee, J. H., Seong, I. W., Cheong, S. S., Lee, B. K., Lee, N. H., ... Park, S. J. (2011). Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial. JACC: Cardiovascular Interventions, 4(10), 1096-1103. https://doi.org/10.1016/j.jcin.2011.05.024

@article{ccfe73843f8746e5b70d65e3579b6476,

title = "Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial",

abstract = "Objectives: This study compared everolimus-eluting stents (EES) and sirolimus-eluting stents (SES) for long coronary lesions. Background: Outcomes remain relatively unfavorable for stent-based coronary intervention of lesions with long diseased segments. Methods: This randomized, multicenter, prospective trial compared the use of long EES with SES in 450 patients with long (<25 mm) native coronary lesions. The primary endpoint of the trial was in-segment late luminal loss at 9-month angiographic follow-up. Results: The EES and SES groups had similar baseline characteristics. Lesion length was 34.0 ± 15.4 mm in the EES group and 34.3 ± 13.5 mm in the SES group (p = 0.85). Nine-month angiographic follow-up was performed in 80\% of the EES group and 81\% of the SES group (p = 0.69). In-segment late loss as the primary study endpoint was significantly larger in the EES group than in the SES group (0.17 ± 0.41 mm vs. 0.09 ± 0.30 mm, p for noninferiority = 0.96, p for superiority = 0.04). The in-segment binary restenosis rate was also higher in the EES group than in the SES group (7.3\% vs. 2.7\%, p = 0.046). However, in-stent late loss (0.22 ± 0.43 mm vs. 0.18 ± 0.28 mm, p = 0.29) and in-stent binary restenosis rate (3.9\% vs. 2.7\%, p = 0.53) were similar among the 2 groups. The incidence of any clinical outcomes (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes) was not statistically different between the 2 groups. Conclusions: For patients with long native coronary artery disease, EES implantation was associated with greater angiographic in-segment late loss and higher rates of in-segment restenosis compared with SES implantation. However, clinical outcomes were both excellent and not statistically different. (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III [LONG-DES-III]; NCT01078038)",

keywords = "angioplasty, coronary disease, stents",

author = "Park, \{Duk Woo\} and Kim, \{Young Hak\} and Song, \{Hae Geun\} and Ahn, \{Jung Min\} and Kim, \{Won Jang\} and Lee, \{Jong Young\} and Kang, \{Soo Jin\} and Lee, \{Seung Whan\} and Lee, \{Cheol Whan\} and Park, \{Seong Wook\} and Yun, \{Sung Cheol\} and Seung, \{Ki Bae\} and Yang, \{Tae Hyun\} and Lee, \{Sang Gon\} and Lee, \{Jae Hwan\} and Seong, \{In Whan\} and Cheong, \{Sang Sig\} and Lee, \{Bong Ki\} and Lee, \{Nae Hee\} and Lee, \{Se Whan\} and Lee, \{Seung Wook\} and Keun Lee and Kim, \{Hyun Sook\} and Jeon, \{Doo Soo\} and Kim, \{Min Kyu\} and Nah, \{Deuk Young\} and Tahk, \{Seung Jea\} and Park, \{Seung Jung\}",

note = "Funding Information: This study was supported by funds from the CardioVascular Research Foundation, Seoul, Korea; a grant from the Korea Health 21 R \& D Project, Ministry of Health \& Welfare , Korea ( 0412-CR02-0704-0001 ); and Boston Scientific , Natick , Massachusetts . Dr. D.-W. Park has received research funding from Boston Scientific. Dr. Y.-H. Kim has received lecture fees from Cordis and Medtronic; and research funding from Boston Scientific. Dr. S.-J. Kang has received lecture fees from Boston Scientific. Dr. S.-W. Lee reports receiving lecture fees from Cordis and Boston Scientific. Dr. C. W. Lee has received lectures fees from Medtronic; and a research grant from Boston Scientific . Dr. S.-W. Park has received research grant support from Medtronic ; and research funding from Boston Scientific. Dr. K.-B. Seung has received lecture fees from Cordis and Boston Scientific. Dr. J.-H. Lee has received research funding from Boston Scientific. Dr. I.-W. Seong has received research grant support from Boston Scientific . Dr. S.-S. Cheong has received lecture fees from Cordis and Boston Scientific. Dr. N.-H. Lee has received lecture fees from Cordis and Boston Scientific. Dr. H.-S. Kim has received consulting fees from Abbott Vascular. Dr. D.-S. Jeon has received lecture fees from Cordis, Medtronic, and Boston Scientific. Dr. D.-Y. Nah has received lecture fees from Cordis and Medtronic. Dr. S.-J. Tahk has received lecture fees from Boston Scientific. Dr. S.-J. Park has received consulting fees from Cordis; lecture fees from Cordis, Medtronic, Boston Scientific, and Abbott; and research grant support from Cordis and Medtronic . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2011",

month = oct,

doi = "10.1016/j.jcin.2011.05.024",

language = "English",

volume = "4",

pages = "1096--1103",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "10",

}

Park, DW, Kim, YH, Song, HG, Ahn, JM, Kim, WJ, Lee, JY, Kang, SJ, Lee, SW, Lee, CW, Park, SW, Yun, SC, Seung, KB, Yang, TH, Lee, SG, Lee, JH, Seong, IW, Cheong, SS, Lee, BK, Lee, NH, Lee, SW, Lee, SW, Lee, K, Kim, HS, Jeon, DS, Kim, MK, Nah, DY, Tahk, SJ & Park, SJ 2011, 'Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial', JACC: Cardiovascular Interventions, vol. 4, no. 10, pp. 1096-1103. https://doi.org/10.1016/j.jcin.2011.05.024

Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial. / Park, Duk Woo; Kim, Young Hak; Song, Hae Geun et al.
In: JACC: Cardiovascular Interventions, Vol. 4, No. 10, 10.2011, p. 1096-1103.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions

T2 - A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial

AU - Park, Duk Woo

AU - Kim, Young Hak

AU - Song, Hae Geun

AU - Ahn, Jung Min

AU - Kim, Won Jang

AU - Lee, Jong Young

AU - Kang, Soo Jin

AU - Lee, Seung Whan

AU - Lee, Cheol Whan

AU - Park, Seong Wook

AU - Yun, Sung Cheol

AU - Seung, Ki Bae

AU - Yang, Tae Hyun

AU - Lee, Sang Gon

AU - Lee, Jae Hwan

AU - Seong, In Whan

AU - Cheong, Sang Sig

AU - Lee, Bong Ki

AU - Lee, Nae Hee

AU - Lee, Se Whan

AU - Lee, Seung Wook

AU - Lee, Keun

AU - Kim, Hyun Sook

AU - Jeon, Doo Soo

AU - Kim, Min Kyu

AU - Nah, Deuk Young

AU - Tahk, Seung Jea

AU - Park, Seung Jung

N1 - Funding Information: This study was supported by funds from the CardioVascular Research Foundation, Seoul, Korea; a grant from the Korea Health 21 R & D Project, Ministry of Health & Welfare , Korea ( 0412-CR02-0704-0001 ); and Boston Scientific , Natick , Massachusetts . Dr. D.-W. Park has received research funding from Boston Scientific. Dr. Y.-H. Kim has received lecture fees from Cordis and Medtronic; and research funding from Boston Scientific. Dr. S.-J. Kang has received lecture fees from Boston Scientific. Dr. S.-W. Lee reports receiving lecture fees from Cordis and Boston Scientific. Dr. C. W. Lee has received lectures fees from Medtronic; and a research grant from Boston Scientific . Dr. S.-W. Park has received research grant support from Medtronic ; and research funding from Boston Scientific. Dr. K.-B. Seung has received lecture fees from Cordis and Boston Scientific. Dr. J.-H. Lee has received research funding from Boston Scientific. Dr. I.-W. Seong has received research grant support from Boston Scientific . Dr. S.-S. Cheong has received lecture fees from Cordis and Boston Scientific. Dr. N.-H. Lee has received lecture fees from Cordis and Boston Scientific. Dr. H.-S. Kim has received consulting fees from Abbott Vascular. Dr. D.-S. Jeon has received lecture fees from Cordis, Medtronic, and Boston Scientific. Dr. D.-Y. Nah has received lecture fees from Cordis and Medtronic. Dr. S.-J. Tahk has received lecture fees from Boston Scientific. Dr. S.-J. Park has received consulting fees from Cordis; lecture fees from Cordis, Medtronic, Boston Scientific, and Abbott; and research grant support from Cordis and Medtronic . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2011/10

Y1 - 2011/10

N2 - Objectives: This study compared everolimus-eluting stents (EES) and sirolimus-eluting stents (SES) for long coronary lesions. Background: Outcomes remain relatively unfavorable for stent-based coronary intervention of lesions with long diseased segments. Methods: This randomized, multicenter, prospective trial compared the use of long EES with SES in 450 patients with long (<25 mm) native coronary lesions. The primary endpoint of the trial was in-segment late luminal loss at 9-month angiographic follow-up. Results: The EES and SES groups had similar baseline characteristics. Lesion length was 34.0 ± 15.4 mm in the EES group and 34.3 ± 13.5 mm in the SES group (p = 0.85). Nine-month angiographic follow-up was performed in 80% of the EES group and 81% of the SES group (p = 0.69). In-segment late loss as the primary study endpoint was significantly larger in the EES group than in the SES group (0.17 ± 0.41 mm vs. 0.09 ± 0.30 mm, p for noninferiority = 0.96, p for superiority = 0.04). The in-segment binary restenosis rate was also higher in the EES group than in the SES group (7.3% vs. 2.7%, p = 0.046). However, in-stent late loss (0.22 ± 0.43 mm vs. 0.18 ± 0.28 mm, p = 0.29) and in-stent binary restenosis rate (3.9% vs. 2.7%, p = 0.53) were similar among the 2 groups. The incidence of any clinical outcomes (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes) was not statistically different between the 2 groups. Conclusions: For patients with long native coronary artery disease, EES implantation was associated with greater angiographic in-segment late loss and higher rates of in-segment restenosis compared with SES implantation. However, clinical outcomes were both excellent and not statistically different. (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III [LONG-DES-III]; NCT01078038)

AB - Objectives: This study compared everolimus-eluting stents (EES) and sirolimus-eluting stents (SES) for long coronary lesions. Background: Outcomes remain relatively unfavorable for stent-based coronary intervention of lesions with long diseased segments. Methods: This randomized, multicenter, prospective trial compared the use of long EES with SES in 450 patients with long (<25 mm) native coronary lesions. The primary endpoint of the trial was in-segment late luminal loss at 9-month angiographic follow-up. Results: The EES and SES groups had similar baseline characteristics. Lesion length was 34.0 ± 15.4 mm in the EES group and 34.3 ± 13.5 mm in the SES group (p = 0.85). Nine-month angiographic follow-up was performed in 80% of the EES group and 81% of the SES group (p = 0.69). In-segment late loss as the primary study endpoint was significantly larger in the EES group than in the SES group (0.17 ± 0.41 mm vs. 0.09 ± 0.30 mm, p for noninferiority = 0.96, p for superiority = 0.04). The in-segment binary restenosis rate was also higher in the EES group than in the SES group (7.3% vs. 2.7%, p = 0.046). However, in-stent late loss (0.22 ± 0.43 mm vs. 0.18 ± 0.28 mm, p = 0.29) and in-stent binary restenosis rate (3.9% vs. 2.7%, p = 0.53) were similar among the 2 groups. The incidence of any clinical outcomes (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes) was not statistically different between the 2 groups. Conclusions: For patients with long native coronary artery disease, EES implantation was associated with greater angiographic in-segment late loss and higher rates of in-segment restenosis compared with SES implantation. However, clinical outcomes were both excellent and not statistically different. (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III [LONG-DES-III]; NCT01078038)

KW - angioplasty

KW - coronary disease

KW - stents

UR - https://www.scopus.com/pages/publications/80054968140

U2 - 10.1016/j.jcin.2011.05.024

DO - 10.1016/j.jcin.2011.05.024

M3 - Article

C2 - 22017935

AN - SCOPUS:80054968140

SN - 1936-8798

VL - 4

SP - 1096

EP - 1103

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 10

ER -

Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this